USPTO serial 87648953
AORTAFIT
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- ALESKOW, DAVID HOWARD
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with AORTAFIT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
James Namiki
JAMES NAMIKI DWC LAW FIRM, P.S.PO BOX 3041SEATTLE, WA 98114UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Software for evaluating patient-specific data, generating case planning information, and providing patient-specific device configurations for use by surgeons in preparing for procedures involving blood vessel grafts, blood vessel stent grafts, endografts, fenestrated endografts, and related devices; software for evaluating patient-specific data and generating patient-specific device configurations for use by manufacturers to provide patient-specific blood vessel grafts, blood vessel stent grafts, endografts, fenestrated endografts, and related devices | ACTIVE | — |
| 042 | Software as a service (SaaS) services featuring software for evaluating patient-specific data, generating case planning information, and providing patient-specific device configurations for use by surgeons in preparing for procedures involving blood vessel grafts, blood vessel stent grafts, endografts, fenestrated endografts, and related devices; software as a service (SaaS) services featuring software for evaluating patient-specific data and generating patient-specific device configurations for use by manufacturers to provide patient-specific blood vessel grafts, blood vessel stent grafts, endografts, fenestrated endografts, and related devices; providing online non-downloadable software for evaluating patient-specific data, generating case planning information, and proposing patient-specific device configurations for use by surgeons in preparing for procedures involving blood vessel grafts, blood vessel stent grafts, endografts, fenestrated endografts, and related devices; providing temporary use of non-downloadable cloud-based software for evaluating patient-specific data, generating case planning information, and proposing patient-specific device configurations for use by surgeons in preparing for procedures involving blood vessel grafts, blood vessel stent grafts, endografts, fenestrated endografts, and related devices; providing online non-downloadable software for evaluating patient-specific data and generating patient-specific device configurations for use by manufacturers to provide patient-specific blood vessel grafts, blood vessel stent grafts, endografts, fenestrated endografts, and related devices; providing temporary use of non-downloadable cloud-based software for evaluating patient-specific data and generating patient-specific device configurations for use by manufacturers to provide patient-specific blood vessel grafts, blood vessel stent grafts, endografts, fenestrated endografts, and related devices | ACTIVE | — |
| 044 | Medical assistance and analysis, namely, evaluating patient-specific data, generating case planning information, and providing patient-specific device configurations for use by surgeons in preparing for procedures involving blood vessel grafts, blood vessel stent grafts, endografts, fenestrated endografts, and related devices; medical assistance and analysis, namely, evaluating patient- specific data and generating patient-specific device configurations for use by manufacturers to provide patient-specific blood vessel grafts, blood vessel stent grafts, endografts, fenestrated endografts, and related devices | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Aortica Corporation
- Other trademarks owned by Aortica Corporation
- Other trademarks in Class 009
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named AORTAFIT
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 15, 2020 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 15, 2020 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 25, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 25, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Feb 11, 2020 | ALIE | ASSIGNED TO LIE | — |
| Jan 28, 2020 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Jan 22, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 22, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 24, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 22, 2019 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Oct 22, 2019 | EXT2 | SOU EXTENSION 2 FILED | — |
| Oct 22, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 11, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 9, 2019 | EX1G | SOU EXTENSION 1 GRANTED | — |
| May 9, 2019 | EXT1 | SOU EXTENSION 1 FILED | — |
| May 9, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 13, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 18, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 18, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 29, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 10, 2018 | ALIE | ASSIGNED TO LIE | — |
| Aug 1, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 31, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 30, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 30, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 1, 2018 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Feb 1, 2018 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Feb 1, 2018 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jan 25, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 26, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 20, 2017 | NWAP | NEW APPLICATION ENTERED | — |